On 22 September 2008, orphan designation (EU/3/08/569) was granted by the European Commission to Enzon (UK) Limited, United Kingdom, for pegylated L-asparaginase for the treatment of acute lymphoblastic leukaemia.
The sponsorship was transferred to Defiante Farmacêutica, S.A., Portugal, in September 2010 and subsequently to Sigma-tau Rare Diseases S.A., Portugal, in November 2012.
|Disease / condition||
Treatment of acute lymphoblastic leukaemia
|Date of first decision||
|EU designation number||
Sponsor's contact details
Rua dos Ferreiros, 260
Tel. +351 291 20 30 70
Fax +351 291 20 30 79
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.